Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist

Aging and Cognitive FunctionsPsychosis and Schizophrenia

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

Psychopharmacology (Berl).

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A

doi: 10.1007/s00213-016-4382-y

Psychosis and Schizophrenia

The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review

J Psychiatr Res.

Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA

doi: 10.1016/j.jpsychires.

Migraine and HeadachePsychosis and Schizophrenia

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial

Schizophr Res.

Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA

doi: 10.1016/j.schres.2016.06.030.

Anxiety and DepressionBipolar Disorder

Cariprazine in the treatment of Bipolar Disorder: A systematic review and meta-analysis

Bipolar Disord.

Pinto JV, Saraf G, Vigo D, Keramatian K, Chakrabarty T, Yatham LN

doi: 10.1111/bdi.12850.

Psychosis and Schizophrenia

On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D_2/3 receptor agonist radioligand study

Transl Psychiatry.

Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Nics L, Pfaff S, Philippe C, Berroterán-Infante N, Pichler V, Meyer BM, Rabl U, Sezen P, Cumming P, Stimpfl T, Sitte HH, Lanzenberger R, Mossaheb N, Zimprich A, Rusjan P, Dorffner G, Mitterhauser M, Hacker M, Pezawas L, Kasper S, Wadsak W, Praschak-Rieder N, Willeit M

doi: 10.1038/s41398-019-0681-5.

Migraine and HeadacheAnxiety and DepressionPsychosis and Schizophrenia

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

Lancet.

Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW

doi: 10.1016/

Psychosis and Schizophrenia

Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis

Acta Psychiatr Scand.

Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A, Sommer IEC, Leucht S, Kahn RS, Luykx JJ

doi: 10.1111/acps.12954.

Psychosis and Schizophrenia

The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study.

Psychiatry Res.

Yoshimura B, Yada Y, So R, Takaki M, Yamada N

doi: 10.1016/

Anxiety and DepressionBipolar DisorderPsychosis and Schizophrenia

Update on schizophrenia and bipolar disorder: focus on cariprazine

Neuropsychiatr Dis Treat.

Roberts RJ, Findlay LJ, El-Mallakh RS

doi: 10.2147/NDT.S97616.

Related content

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial

Cariprazine in the treatment of Bipolar Disorder: A systematic review and meta-analysis

On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis

The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study.

Update on schizophrenia and bipolar disorder: focus on cariprazine

On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D_2/3 receptor agonist radioligand study